These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28754829)

  • 1. Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".
    Barreto AD; Grotta JC
    Stroke; 2017 Sep; 48(9):e259. PubMed ID: 28754829
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Shah Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".
    Shah NH
    Stroke; 2017 Sep; 48(9):e258. PubMed ID: 28754831
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy.
    Carandang RA
    JAMA Neurol; 2016 Mar; 73(3):265-7. PubMed ID: 26810152
    [No Abstract]   [Full Text] [Related]  

  • 6. Response by Sposato et al to Letter Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".
    Sposato LA; Wardlaw JM; Hachinski V
    Stroke; 2017 Mar; 48(3):e92. PubMed ID: 28174325
    [No Abstract]   [Full Text] [Related]  

  • 7. Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.
    Deguchi I; Mizuno S; Kohyama S; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Jan; 27(1):61-67. PubMed ID: 28867523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
    Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
    Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter by Alves et al Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".
    Alves JN; Pinho J; Ferreira C
    Stroke; 2017 Mar; 48(3):e91. PubMed ID: 28174329
    [No Abstract]   [Full Text] [Related]  

  • 10. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
    Jauch EC; Lindsell C; Broderick J; Fagan SC; Tilley BC; Levine SR;
    Stroke; 2006 Oct; 37(10):2508-13. PubMed ID: 16960091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
    Tanne D; Macko RF; Lin Y; Tilley BC; Levine SR;
    Stroke; 2006 Jul; 37(7):1798-804. PubMed ID: 16763191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological issues for designing and conducting a multicenter, international clinical trial in Acute Stroke: Experience from ARTSS-2 trial.
    Rahbar MH; Dickerson AS; Cai C; Pedroza C; Hessabi M; Shen L; Pandurengan R; Jacobs ANM; Indupuru H; Sline MR; Delgado RI; Macdonald C; Ford GA; Grotta JC; Barreto AD
    Contemp Clin Trials; 2015 Sep; 44():139-148. PubMed ID: 26278031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argatroban tPA stroke study: study design and results in the first treated cohort.
    Sugg RM; Pary JK; Uchino K; Baraniuk S; Shaltoni HM; Gonzales NR; Mikulik R; Garami Z; Shaw SG; Matherne DE; Moyé LA; Alexandrov AV; Grotta JC
    Arch Neurol; 2006 Aug; 63(8):1057-62. PubMed ID: 16908730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.
    Hsieh HC; Chen CH
    Clin Neurol Neurosurg; 2009 Jul; 111(6):562-3. PubMed ID: 19200644
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Liao X; Wang Y; Wang Y
    Stroke; 2014 Dec; 45(12):e304. PubMed ID: 25342031
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to letter regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Coutts SB; Hill MD
    Stroke; 2015 Jun; 46(6):e150. PubMed ID: 25899240
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter by Wu et al Regarding Article, "Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus".
    Wu C; Ma H; Ji X
    Stroke; 2019 Sep; 50(9):e271. PubMed ID: 31370768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.